1,2; I. Svobodová
1,2; M. Kucerova
1,2; L. Brozova
1,2; J. Muzik
1,2; J. Jarkovský
1,2; R. Hájek
3; V. Maisnar
4; L. Dusek
Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
1; Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic
2; Department of Haematooncology, University Hospital Ostrava and the Faculty of Medicine, University of Ostrava, Czech Republic
3; 4th Department of Internal Medicine – Haematology, Charles University Hospital, Hradec Kralove, Czech Republic
Klin Onkol 2017; 30(Supplementum2): 35-42
Background: Multiple myeloma (MM) is a cancer of plasma cells with an incidence of 4.8 cases per 100,000 population in the Czech Republic in 2014; the burden of MM in the Czech Republic is moderate when compared to other European countries. This work brings the latest information on MM epidemiology in the Czech population.
Material and Methods: The Czech National Cancer Registry is the basic source of data for the population-based evaluation of MM epidemiology. This database also makes it possible to assess patient survival and to predict probable short-term as well as long-term trends in the treatment burden of the entire population.
Results: According to the latest Czech National Cancer Registry data, there were 504 new cases of MM and 376 deaths from MM in 2014. Since 2004, there has been a 26.9% increase in MM incidence and an 8.3% increase in MM mortality. In 2014, there were 1,982 persons living with MM or a history of MM, corresponding to a 74.4% increase when compared to MM prevalence in 2004. The 5-year survival of patients treated in the period 2010–2014 was nearly 40%.
Conclusion: The available data make it possible to analyse long-term trends in MM epidemiology and to predict the future treatment burden as well as treatment results.
Key words: multiple myeloma – epidemiology – Czech National Cancer Registry – Registry of Monoclonal Gammopathies – Czech Republic
The importance of cancer epidemiology has been growing steadily, partly as a result of a high cancer incidence worldwide. The Czech Republic is no exception in this regard; on the contrary, it is one of the countries with the highest burden in several cancer types. Tens of thousands of cancer patients are newly diagnosed in the Czech Republic each year, and hundreds of thousands of them are followed-up due to a history of cancer in the past. This work aims to describe epidemiological trends of multiple myeloma (MM) in the Czech population, to assess patient survival and to predict probable short-term as well as long-term trends in the treatment burden of the entire population.
Material and methods
High-quality data play a key role in the evaluation of cancer epidemiology; in particular, the following data sources  are used for this purpose in the Czech Republic:
Data on demographic structure of the Czech Republic population are processed by the Czech Statistical Office (CZSO) as part of its monitoring of the Czech population. These data cover demographic characteristics of the population, such as the total number of population, age structure, life expectancy etc. [2,3]. Population-based cancer mortality data are stored in a database of causes of death which is also processed by CZSO, in accordance with international methodology and based on data from death certificates (ICD-10 classification).
The Czech National Cancer Registry (CNCR) is the main source of data on cancer epidemiology. CNCR is nowadays an integral part of comprehensive cancer care, covering 100% of the Czech population and containing more than 2.2 million records from the period 1977–2014. MM accounts for 0.6% of these records. The registration of malignant tumours is enshrined in the Czech legislation and is obligatory. CNCR is also the source of data for the assessment of basic performance indicators of cancer care, particularly for the assessment of patient survival. This work uses the estimate of 5-year relative survival  for this purpose. The Czech Society for Oncology has used CNCR data to develop an information system that predicts both the population burden of cancer as well as treatment burden for future periods. These predictions resulted from modelling of the development of demographic structure and cancer incidence in the population; survival models leading to predictions of prevalence of cancer patients to be treated in near future are another important component. The methodology and applied prediction scenarios are described in a publication by Dušek et al. .
The Registry of Monoclonal Gammopathies (RMG), established in 2007 by the Czech Myeloma Group, is another source of data. RMG represents an international database designed for the collection of data on patients with MM and other types of monoclonal gammopathies. Nineteen Czech centres and four Slovak centres currently contribute to the registry. The registry already contains data on more than 5,000 patients with MM (visit https: //rmg.healthregistry.org to find more information). RMG not only contains data on MM incidence, but also makes it possible to monitor the use of individual treatment modalities, the occurrence of adverse events and drug toxicity . RMG is therefore one of the largest and most comprehensive registries with regular monitoring in Europe. Treatment with all available therapies is recorded into the registry, thus making RMG a valuable source of data from real clinical practice. RMG represents a data basis that makes it possible to monitor the disease course on the population level. Data from RMG are utilised in the preparation of national guidelines for treatment of monoclonal gammopathies, serve as a basis for negotiations with the State Institute for Drug Control, and are also used for subsequent negotiations on reimbursements of new drugs with healthcare payers.
The database GLOBOCAN 2012, which is available at http: //globocan.iarc.fr/, is the international source of data on cancer epidemiology. In view of the fact that these data are always available with a certain delay, this work presents estimated values for the year 2012, based on the most recent data available at the time of processing [7,8].
International comparison of MM epidemiology
The estimated incidence of MM in 2012 was 114,251 new cases globally (23rd most common cancer, accounting for 0.8% of all cancers excluding non-melanoma skin cancer) and 38,956 new cases in Europe (21st most common cancer, accounting for 1.1% of all cancers excluding non-melanoma skin cancer). The cumulative risk of developing MM before the age of 74 is 0.17% globally (0.20% in men, 0.15% in women) and 0.31% in Europe (0.38% in men, 0.26% in women). The estimated mortality of MM in 2012 was 80,019 deaths globally (20th most common cause of cancer deaths, accounting for 1.0% of all cancer deaths excluding non-melanoma skin cancer) and 24,300 deaths in Europe (16th most common cause of cancer deaths, accounting for 1.4% of all cancer deaths excluding non-melanoma skin cancer). The estimated 5-year prevalence of MM in 2012 (i.e. the number of persons diagnosed within 5 previous years and still alive in 2012) was 229,468 globally (4.4 per 100,000 population) and 89,187 in Europe (14.3 per 100,000 population). Table 1 provides the basic overview of epidemiological characteristics of MM in Europe. Recent statistics have also clearly shown that the burden of MM in the Czech Republic – in terms of both incidence and mortality – is moderate when compared to other European countries [7,8].
Epidemiology of MM in the Czech Republic
For the purpose of analysis of data from CNCR, neoplasms with diagnosis C90.0 (according to the International Statistical Classification of Diseases and Related Health Problems – 10th Revision, ICD-10) and neoplasms with morphology code 9732/3 (according to the International Classification of Diseases for Oncology – 3rd edition, ICD-O-3) were included in the group of MM.
Trends in MM incidence and mortality in the Czech Republic over more than three decades are shown in Fig. 1A. There has been a significant and consistent increase not only in incidence rates, but also in mortality rates (however, European age-standardised mortality rate is stabilised). Between 1980 and 2014, MM incidence increased from 2.3 to 4.8 new cases per 100,000 population and MM mortality increased from 1.4 to 3.6 deaths per 100,000 population. In absolute numbers in 2014, MM incidence was 504 new cases, MM mortality was 376 deaths and MM prevalence (i.e. all cases diagnosed in the past and still alive in 2014) was 1,982 persons (corresponding to 18.8 per 100,000 population). Although the incidence of MM in the Czech Republic is low when compared to other cancer types, its prevalence has been growing over the years (Fig. 1B) and the absolute number of persons with a history of MM, who need to be followed-up, is certainly not negligible. The overall epidemiological situation of MM in the Czech Republic in the period 2010–2014 is summarised in Tab. 2.
MM is mostly diagnosed in older people – the median age is 68 years in men and 70 years in women. Incidence rates are highest between the age of 61 and 75 years in men and between the age of 62 and 78 years in women (Fig. 2A). At the time of diagnosis, less than 1% of all MM patients are under the age of 40, and 18.6% of all MM patients are under the age of 60. Age-specific incidence rates, shown in Fig. 2B, demonstrate the growing risk of developing MM in older age. Age-specific incidence rates rise sharply from around age 45.
MM as a subsequent primary cancer in the same patient
The occurrence of subsequent primary cancers in the same patient significantly contributes to the overall epidemiological burden of the Czech population. A detailed analysis of historical data from CNCR has revealed a significant increase in the number of cases of MM as subsequent primary cancers over time (Tab. 3). Until 1994, these cases accounted for less than 5% of the overall number of new cases of MM. This proportion grew to almost 9% in the period 1995–2004, and available data from 2014 have shown that as much as 17% of all newly diagnosed cases of MM were subsequent primary cancers. Nowadays, MM is expected to be diagnosed as a subsequent primary cancer in about 80 persons each year.
MM incidence according to data from CNCR vs. RMG
Comparison of the number of patients according to the CNCR with the number of patients according to the RMG shows that RMG covers approximately 80% of data contained in CNCR for the period 2007–2014.
Predicted numbers of MM patients to be treated
Table 4 shows the estimates of incidence, prevalence and number of MM patients who will probably be treated in 2017. The estimate of overall prevalence involves both the number of newly diagnosed patients in 2017 and the estimated number of living patients who were diagnosed and treated in previous years (calculated by population survival models). The overall sum for 2017 expects at least 2,079 newly treated patients (with a 90% CI ranging between 1,876 and 2,303); in case of optimally full reimbursements, the predicted number of newly treated patients is 2,680 (2,442; 2,936).
The predicted numbers of patients are updated each year and provided to healthcare payers as a background for their planning of treatment costs. Determination of the number of patients to be treated, which is based on the epidemiological situation, provides population-based reference data for a subsequent monitoring of clinical practice. In this way, the Czech Society for Oncology and healthcare payers are informed about the availability of therapy nationwide and in individual regions. It has been repeatedly shown that the numbers of actually treated patients do not substantially exceed the epidemiologically estimated burden.
Assessment of results of care provided to MM patients
The 5-year relative survival is the most common measure to describe the seriousness of a given cancer type on a population level, expressing the proportion of patients who have not died from that cancer type within 5 years of diagnosis. The relative survival is calculated as the ratio of the overall survival (representing the overall observed mortality in a cohort of patients with a given cancer type) and the so-called expected survival (representing the mortality in a general population which corresponds in age and sex to the monitored group of patients). In other words, the relative survival describes the overall survival adjusted to mortality related to other diseases which the patient might die of. Furthermore, relative survival rates are age-standardised due to different age structures of patients in individual time periods; this means that the resulting survival is obtained as a weighted mean of relative survival rates in defined age categories [9,10].
In this regard, population-based data from CNCR provide the possibility of a very valuable assessment of the overall survival of cancer patients. Table 5 shows the assessment of relative survival of MM patients in the Czech Republic. Comparison of different time periods shows that there has been a significant increase in the 5-year survival of MM patients over time: the 5-year relative survival of MM patients who had been diagnosed before 2000 was 27.0%; by contrast, the 5-year relative survival of MM patients who were treated with anticancer therapy was almost 40% in the period 2010–2014.
The aim of this work was to describe epidemiological trends of MM in the Czech population, to assess patient survival and to predict probable short-term trends in the treatment burden of the entire population. This work proves that adequate data sources are available for the above-mentioned analyses. Each year in the Czech Republic, about 500 people are newly diagnosed with MM and about 350 people die of it. MM prevalence – i.e. the number of persons living with MM or a history of MM – was 1,982 in 2014, corresponding to a 74.4% increase when compared to MM prevalence in 2004. The probability of 5-year survival of MM patients has significantly increased over the last 20 years.
This work was supported by the project Development of the NHIS Technology Platform – CZ.03.4.74/0.0/0.0/15_019/0002748.
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
prof. MUDr. Roman Hajek, CSc.
Department of Haematooncology University Hospital Ostrava
17. listopadu 1790
708 52 Ostrava
Submitted: 9. 6. 2017
Accepted: 17. 6. 2017
1. Dušek L, Žaloudík J, Indrák K. Informační zázemí pro využití onkologických populačních dat v ČR. Klin Onkol 2007; 20 (Suppl 1): 52–196.
3. Ústav zdravotnických informací a statistiky ČR. Národní zdravotnický informační systém (NZIS), Národní onkologický registr (NOR). [online]. Dostupné z: http: //www.uzis.cz/registry-nzis/nor.
4. Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe: a 2000–2002 period analysis of EUROCARE-4 data. Lancet Oncol 2008; 8 (9): 784–796.
5. Dušek L (ed.). Czech Cancer Care in Numbers 2008–2009. Praha: Grada Publishing 2010.
6. Maisnar V, Pelcová J, Klimeš D et al. RMG – Registr monoklonálních gamapatií. Onkologie 2011; 5 (3): 138–140.
7. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. [online]. Available from: http: //globocan.iarc.fr.
8. Bray F, Ren JS, Masuyer E et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132 (5): 1133–1145. doi: 10.1002/ijc. 27711.
9. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monog 1961; 6: 101–121.
10. Brenner H, Hakulinen T. On crude and age-adjusted relative survival rates. J Clin Epidemiol 2003; 56 (12): 1185–1191.
Paediatric clinical oncology